OR WAIT null SECS
Rita C. Peters is editorial director of BioPharm International, Pharmaceutical Technology, and Pharmaceutical Technology Europe.
America's biopharmaceutical companies are using biological processes to develop 907 medicines and vaccines targeting more than 100 diseases, according to a new report.
America's biopharmaceutical companies are using biological processes to develop 907 medicines and vaccines targeting more than 100 diseases, according to a
released today by the Pharmaceutical Research and Manufacturers of America (PhRMA).
The report includes biologics in human clinical trials or under review by FDA such as 338 cancer therapeutics that target several different types of solid tumors, leukemia and lymphoma; 134 vaccines for infectious diseases; 71 medicines for autoimmune diseases including lupus, multiple sclerosis, and rheumatoid arthritis; and 58 treatments for cardiovascular disease.
Among the biologic medicines in development are a genetically-modified virus-based vaccine to treat melanoma; a monoclonal antibody for the treatment of asthma; an antisense therapy for the treatment of leukemia; a recombinant fusion protein to treat Type II diabetes.
The report lists the product name, sponsor, product category, indication, and development phase.